The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
DICERNA PHARMACEUTICALS INC COM 253031108   89,888 4,080,237 SH   SOLE   4,080,237 0 0
MARINUS PHARMACEUTICALS INC COM 56854Q101   12,836 5,942,735 SH   SOLE   5,942,735 0 0
REPLIMUNE GROUP INC COM 76029N106   40,739 2,838,968 SH   SOLE   2,838,968 0 0
SOLID BIOSCIENCES INC COM 83422E105   17,227 3,871,164 SH   SOLE   3,871,164 0 0
APTINYX INC COM 03836N103   7,610 2,225,092 SH   SOLE   2,225,092 0 0
SPRINGWORKS THERAPEUTICS INC COM 85205L107   280,258 7,281,307 SH   SOLE   7,281,307 0 0
DYNAVAX TECHNOLOGIES CORP. COM 268158201   48,347 8,452,235 SH   SOLE   8,452,235 0 0
CONSTELLATION PHARMACEUTICALS INC. COM 210373106   133,016 2,823,529 SH   SOLE   2,823,529 0 0
X4 PHARMACEUTICALS INC COM 98420X103   17,639 1,648,485 SH   SOLE   1,648,485 0 0
SAVARA INC COM 805111101   22,976 5,128,593 SH   SOLE   5,128,593 0 0